Pharming Group Issues 2026 Financial Guidance and Highlights Advancing Rare Disease Pipeline

summarizeSummary

Pharming Group N.V. announced its 2026 financial guidance, projecting 8% to 13% revenue growth, and provided updates on its clinical-stage rare disease pipeline, including leniolisib expansion and the newly named napazimone (KL1333) program.

check_boxKey Events

• 2026 Revenue Guidance

  Pharming Group projects total revenues between US$405 million and US$425 million for 2026, representing 8% to 13% growth, driven by Joenja® and RUCONEST®.

• Operating Expense Guidance

  Total operating expenses for 2026 are guided between US$330 million and US$335 million, primarily due to increased R&D for ongoing leniolisib Phase II trials and the napazimone (KL1333) pivotal trial.

• Pipeline Expansion for Leniolisib

  The company is expanding leniolisib into broader primary immunodeficiencies (PIDs) and common variable immunodeficiency (CVID) with immune dysregulation, with Phase II top-line data expected in H2 2026.

• Napazimone (KL1333) Update

  KL1333, for mtDNA-driven mitochondrial disease, has been named napazimone, with its pivotal FALCON clinical trial on track for a readout in 2027.

auto_awesomeAnalysis

This filing provides a positive outlook for Pharming Group, projecting significant revenue growth for 2026, which follows a recent preliminary 2025 revenue beat. The company also detailed its advancing rare disease pipeline, emphasizing the expansion of leniolisib into broader primary immunodeficiencies and the progress of napazimone (KL1333) for mtDNA-driven mitochondrial disease. These updates, presented at an Investor Day, aim to reinforce investor confidence in the company's long-term growth strategy, especially after the recent Complete Response Letter from the FDA regarding Joenja® for a pediatric indication.